Phase I study of LIQ-861 in healthy volunteers.

Trial Profile

Phase I study of LIQ-861 in healthy volunteers.

Phase of Trial: Phase I

Latest Information Update: 10 Jan 2018

At a glance

  • Drugs LIQ-861 (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions
  • Sponsors Liquidia Technologies
  • Most Recent Events

    • 10 Jan 2018 New trial record
    • 03 Jan 2018 According to the Liquidia Technologies, company expects to reports additional data from this study scientific conferences in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top